ABIO Stock Summary and Trading Ideas (Arca Biopharma | NASDAQ:ABIO)

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Arca Biopharma trades on the NASDAQ stock market under the symbol ABIO.

As of March 27, 2023, ABIO stock price declined to $2.07 with 7,178 million shares trading.

ABIO has a beta of 0.23, meaning it tends to be less sensitive to market movements. ABIO has a correlation of 0.03 to the broad based SPY ETF.

ABIO has a market cap of $29.83 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ABIO stock traded as high as $22.00 and as low as $1.71.

The top ETF exchange traded funds that ABIO belongs to (by Net Assets): VTI, VXF, IWC, DFAT, ITOT.

ABIO has underperformed the market in the last year with a price return of -13.0% while the SPY ETF lost -10.4%. ABIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.9% and -5.0%, respectively, while the SPY returned +4.1% and +3.3%, respectively.

ABIO support price is $2.02 and resistance is $2.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABIO stock will trade within this expected range on the day.